Low-dose MRI contrast gets FDA approval, Bayer's Ambelvist arrives in the U.S.

Edited by ad hoc news Products & Consumer Desk. Reviewed before publication on 06/15/2026 at 8:21 PM ET. Details in the imprint.

Bayer's Ambelvist, the new MRI contrast agent built around gadoquatrane, has cleared the FDA and is now approved in the U.S. for contrast-enhanced magnetic resonance imaging in adults, pediatric patients and term neonates. Bayer says the product is the lowest-dose macrocyclic gadolinium-based contrast agent approved in the U.S., with a recommended dose of 0.01 mmol/kg actual body weight. official Bayer announcement

Why this approval matters for radiology

The label covers imaging of lesions with abnormal vascularity in the central nervous system and in body regions such as the head and neck, thorax, abdomen, pelvis and musculoskeletal system. That makes Ambelvist relevant to routine radiology workflows rather than a narrow niche indication, and it extends Bayer's radiology portfolio at a moment when dose minimization is a selling point in contrast-agent design. Pharmaceutical Technology coverage

Bayer also links the U.S. approval to its Phase III QUANTI program, which it says supported the filing and underpinned the lower-dose positioning versus older mGBCA standards. Market Screener reported the same launch-day details and noted that the compound had already been approved in Japan in March 2026, with additional global submissions still underway. Market Screener report

Ambelvist fits Bayer's pharmaceuticals division as a specialized imaging product with clear hospital use, not a consumer-facing launch. Shares of Bayer AG (DE000BAY0017) traded in Frankfurt at EUR 25.11 on 06/15/2026, reflecting how the stock still serves mainly as a backdrop to the company-specific product story.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.